14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
NEXR vs CMND: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Clearmind Medicine Inc. Common Shares (CMND) is the stronger overall head-to-head candidate over NEXR (NEXR) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NEXR carries a Unified Composite Score of 31.0/100 (SELL) at $1.38 (N/M Forward P/E, N/A operating margin), whereas CMND carries 49.8/100 (HOLD) at $4.18 (N/M Forward P/E, 0.0% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NEXR vs CMND. Trailing 12-month operating profitability (NEXR N/A vs CMND 0.0%) and valuation multiples (NEXR N/M vs CMND N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.3M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ NEXR vs CMND Key Questions & Quantitative Answers
As of Nov 16, 2026, Clearmind Medicine Inc. Common Shares (CMND) is the stronger overall head-to-head candidate over NEXR (NEXR) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). NEXR carries a Unified Composite Score of 31.0/100 (SELL) at $1.38 (N/M Forward P/E, N/A operating margin), whereas CMND carries 49.8/100 (HOLD) at $4.18 (N/M Forward P/E, 0.0% operating margin). Technically, NEXR sits in a Neutral phase (RSI 54.5, UNCLASSIFIED options structure) and CMND sits in a Neutral phase (RSI 34.4, UNCLASSIFIED options structure).
CMND leads the Growth & Scale pillar: NEXR posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with CMND at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, NEXR generates N/A in USD-normalized revenue versus N/A for CMND. In operating R&D and SG&A reinvestment, NEXR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CMND.
NEXR and CMND trade at balanced relative valuation multiples. NEXR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas CMND trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NEXR (N/A ROE) versus CMND (-107.0% ROE) capital efficiency.
In options market volatility and institutional positioning, NEXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (8.42β · 2730% Vol realized risk). By comparison, CMND carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.87β · 58% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.